Can neoadjuvant chemotherapy change clinic pathological and survival parameters in HER-2 positive breast cancer patients?

被引：0
|
作者：
Mundim, F. [1 ]
Franco, A. [1 ]
Infante, K. [1 ]
Neto, J. [1 ]
Brentani, M. M. [1 ]
Facina, G. [1 ]
Waitzberg, A. [1 ]
机构：
[1] Univas Brazil, Pathol, Pouso Alegre, Brazil
来源：
VIRCHOWS ARCHIV | 2018年 / 473卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-02-04
引用
收藏
页码：S209 / S209
页数：1
相关论文
共 50 条
  • [31] Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy
    Nunes, Raquel A.
    Li, Xiaochun
    Kang, Soonmo Peter
    Burstein, Harold
    Roberts, Lisa
    Carney, Walter
    Blackwell, Kimberly
    Ryan, Paula
    Borges, Virginia
    Iglehart, J. Dirk
    Friedman, Paula
    Harris, Lyndsay N.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2009, 24 (01): : 1 - 10
  • [32] Assessment of overall survival benefit from neoadjuvant chemotherapy in elderly HER-2 negative breast cancer patients: A population-based study
    Lv, W.
    Liu, Y.
    Wu, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S1415 - S1415
  • [33] Clinical implication of HER2 status change after neoadjuvant chemotherapy with Trastuzumab and Pertuzumab (HP) in patients with HER2-positive breast cancer
    Ferraro, Emanuela
    Safonov, Anton
    Wen, Hanna Y.
    Brogi, Edi
    Gonan, Mithat
    Barrio, Andrea V.
    Razavi, Pedram
    Chandarlapaty, Sarat
    Modi, Shanu
    Seidman, Andrew D.
    Norton, Larry
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2022, 82 (04)
  • [34] Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients
    Vici, P.
    Viola, G.
    Botti, C.
    Rossi, S.
    Vitucci, C.
    Corsetti, S.
    Di Lauro, L.
    Sergi, D.
    Foggi, P.
    Perri, P.
    Tirellil, C.
    Mottolese, M.
    Fattoruso, S. I. S.
    Lopez, M.
    CLINICA TERAPEUTICA, 2008, 159 (06): : 449 - 452
  • [35] Drug Holidays in Patients with HER-2 Positive Metastatic Breast Cancer
    Kurtom, Saba
    Senol, Kazim
    Sabih, Qurat Ul Ain
    Sezgin, Efe
    Brufsky, Adam
    Gorantla, Vikram
    Puhalla, Shannon
    Soran, Atilla
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer
    Tomohiro Ochi
    Hiroko Tsunoda
    Naoko Matsuda
    Fumi Nozaki
    Koyu Suzuki
    Hiroyuki Takei
    Hideko Yamauchi
    Breast Cancer, 2021, 28 : 838 - 847
  • [37] Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer
    Ochi, Tomohiro
    Tsunoda, Hiroko
    Matsuda, Naoko
    Nozaki, Fumi
    Suzuki, Koyu
    Takei, Hiroyuki
    Yamauchi, Hideko
    BREAST CANCER, 2021, 28 (04) : 838 - 847
  • [38] HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
    Lillemoe, Tamera J.
    Rendi, Mara
    Tsai, Michaela L.
    Knaack, Monica
    Yarosh, Rina
    Grimm, Erin
    Susnik, Barbara
    Krueger, Janet
    Olet, Susan
    Swenson, Karen K.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2021, 2021
  • [39] Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer
    Qiao, Weiqiang
    Guo, Wanying
    Liu, Qipeng
    Guo, Xiao
    Deng, Miao
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 64
  • [40] Correlation between Neoadjuvant Chemotherapy Response and ER, PGR and Her-2 Expression in Breast Cancer
    Tanvir, Imrana
    Riaz, Sabiha
    Khan, Haseeb Ahmed
    Loya, Asif
    Khan, Huma Majeed
    Khan, Rizwan Ullah
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2013, 7 (03): : 614 - 617
12345